Pfizer Inc. has announced an exclusive global licensing agreement with 3SBio, Inc., a prominent Chinese biopharmaceutical company, for the development, manufacturing, and commercialization of SSGJ-707. This bispecific antibody targets PD-1 and VEGF and is currently involved in clinical trials in China for various cancers, including non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. Under the agreement, Pfizer will gain an exclusive global license, excluding China, and will make a $100 million equity investment in 3SBio upon closing, subject to customary conditions and approvals. Additionally, 3SBio will receive an upfront payment of $1.25 billion and may receive up to $4.8 billion in milestone payments. Tiered double-digit royalties on sales of SSGJ-707, if approved, are also part of the agreement. Pfizer plans to produce the drug substance in Sanford, North Carolina, and the drug product in McPherson, Kansas.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。